India, Nov. 12 -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company, reported financial results for the third quarter ended September 30, 2026, and provided updates on its clinical development programmes, including its registrational Phase 3 AURORA trial of denifanstat for moderate to severe acne.
The company highlighted positive Phase 3 results from its license partner Ascletis in China, progress in its U.S. clinical programme, and an October equity financing that strengthened its cash position.
Company Profile
Sagimet Biosciences develops inhibitors of fatty acid synthase (FASN), a key regulator of lipid synthesis involved in acne and other diseases.
Its lead candidate, denifanstat, is an oral, once-daily FAS...